- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Testing Episodic Memory in Elderly Subjects: Not as Simple as It Looks ; volume:9 ; number:2 ; year:2019 ; pages:207-216
Dementia and geriatric cognitive disorders / Extra. Extra ; 9, Heft 2 (2019), 207-216
- Urheber
-
Boelaarts, Leo
Meyer, Sascha R.A.
Scheltens, Philip
de Jonghe, Jos F.M.
- DOI
-
10.1159/000499836
- URN
-
urn:nbn:de:101:1-2019110623180968136171
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Boelaarts, Leo
- Meyer, Sascha R.A.
- Scheltens, Philip
- de Jonghe, Jos F.M.
Ähnliche Objekte (12)
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited
The “rights” of precision drug development for Alzheimer’s disease
Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light - a randomized clinical trial
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited
The “rights” of precision drug development for Alzheimer’s disease
Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light - a randomized clinical trial
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited
The “rights” of precision drug development for Alzheimer’s disease
Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light - a randomized clinical trial
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial